(3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acid
Modify Date: 2024-04-02 14:53:21
![(3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acid Structure](https://image.chemsrc.com/caspic/359/804-53-5.png)
(3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acid structure
|
Common Name | (3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acid | ||
|---|---|---|---|---|
| CAS Number | 804-53-5 | Molecular Weight | 413.52800 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C20H31NO6S | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of (3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acidTetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease[1][2][3]. |
| Name | (3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydrobenzo[a]quinolizin-2-one,methanesulfonic acid |
|---|---|
| Synonym | More Synonyms |
| Description | Tetrabenazine (Ro 1-9569) mesylate is a reversible inhibitor of the vesicular monoamine transporter VMAT2 with the Kd value of 1.34 nM. Tetrabenazine mesylate can be used for research on diseases related to hyperactive movement disorders such as Huntington's disease[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vivo | Tetrabenazine mesylate (subcutaneous injection, 1-10 mg/kg, once, 10 min) can reduce the aggressive behavior in a dose-dependent manner and the levels of neurotransmitter molecules NE, DA and 5-HT in adult male mice[1]. Tetrabenazine mesylate (intraperitoneal injection, 0-2 mg/kg, once, 30min) has selective effects on movement which can significantly attenuate morphine-induced hypermobility but oral tremors and stereotyped behaviors in male ICR mice[2]. Tetrabenazine mesylate (intraperitoneal injection, 0.25-2 mg/kg, once a week) increases tremulous jaw movement (TJM) in a dose-dependent manner in adult male Sprague-Dawley rat[3]. Animal Model: Adult male MAO A KO or wide type mice aged 1-2 months[1] Dosage: 1-10 mg/kg Administration: Subcutaneous injection; once; 10 min Result: Completely eliminated the aggressive behavior at a concentration of 5 mg/kg and significantly reduced their NE, DA and 5-HT levels. Animal Model: Male ICR mice (10 weeks old)[2] Dosage: 0-2 mg/kg Administration: Intraperitoneal injection; once; 30min Result: Attenuated the subsequent morphine-induced hypermobility after pretreatment with tetrabenazine. Reduced METH-induced increases in locomotion at 1 mg/kg. Animal Model: Adult male Sprague-Dawley rat weighed 350-450 g[3] Dosage: 0.25-2 mg/kg Administration: Intraperitoneal injection; once a week Result: Induced tremulous jaw movement (TJM) significantly at the concentration of 2 mg/kg and more motor impairments with higher doses such as 3-4 mg/kg. |
| References |
| Molecular Formula | C20H31NO6S |
|---|---|
| Molecular Weight | 413.52800 |
| Exact Mass | 413.18700 |
| PSA | 101.52000 |
| LogP | 3.76080 |
| Tetrabenazine methanesulfonate |
| UNII-5X57I1N37U |